BioBusiness

The challenge is to determine the optimal frequency for preventive maintenance and the optimal frequency and tolerances for calibration readings.

In case you haven't heard, Jeffrey Kindler, Pfizer's general counsel, is replacing long-time CEO Henry "Hank" McKinnell as the new head of the company. There is a long-range strategy in naming a lawyer to run a drug company and I'll get to that in a moment.

Better supplier management can begin in parallel to production-related improvements.

China is becoming a much more sophisticated economy, with a large and well-educated workforce.

Wyeth today relies on biotech product revenue to drive approximately 25% of its revenues.

When former Federal Reserve chairman Alan Greenspan's term in office expired on January 31, 2006, many people said, "There goes a legend." Maybe the better expression was, "Here comes the spin."

In 2005, 10 biopharma- ceuticals gained marketing approval in the US or Europe, although only five of them were genuinely new molecular entities.

Congress is not considering legislation that would expand FDA authority to regulate biologics.

Many CMO relationships are established while a product is early in clinical or preclinical development.

Buffett prefers to buy small, publicly traded companies with ample room for growth.

Food and Drug Administration is encouraging public–private collaborations to more fully explore the physical and chemical characteristics of nanoparticles.

The lack of biomanufacturer acquisitions seems surprising.

The courts regard biotechnology as highly unpredictable

Without generic competition, the US is at risk of losing its position of leadership in biopharmaceuticals.

Disposables can be used for media preparation, clarification, filling in downstream processes . . .

The top 10 Chinese companies in the biopharm sector account for only 20% of the market... leaving plenty of room for growth for Western companies.

Motorola recognized that vartion is the death knell of any process, so the company established a methodology called Six Sigma

Certain areas of the vaccine market appear to be in vogue again, revitalized by blockbusters such as Prevnar, the pneumococcal pneumonia vaccine that reaped $1.5 billion in sales last year, and the human papilloma virus vaccines, which are projected to reach $4 billion per year.

Only the product that served as the basis of the extension is exclusively covered by the patent during its extended term.

The federal government plans to spend $3.3 billion on bird flu initiatives, about half of that on a vaccine.

Coming from Wall Street. I'm often asked what "professional" investors think about the life sciences industry.

Interestingly, it is companies that already have the most capacity available to them that are building even more.

Of all the protein products on the US market, at most 75 are likely to become genericized.

A powerful film will have a hundred times the impact of a touchy-feely commercial.

Minimum disruption and maximum gain result when adopting a distributed process control and data management system for a cell culture and fermentation lab.